Pierre Dillard

Janssen (France) — France

Medicine · Health Sciences

14h-index722citations35works3.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(21), Immunotherapy and Immune Responses(11), Virus-based gene therapy research(6), T-cell and B-cell Immunology(5), Monoclonal and Polyclonal Antibodies Research(5)

Publications35 total

Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.
PubMed·2026
FRI-359 A 5-week treatment with the GLP-1/GIP/glucagon triple receptor agonist retatrutide demonstrates multiple metabolic benefits and strong reduction in liver steatosis in a diet-induced obese MASH mouse model
Journal of Hepatology·2025
Morphodynamics of T-lymphocytes: Scanning to spreading
Biophysical Journal·2024· 11 citedOpen Access
Efficient chimeric antigen receptor targeting of a central epitope of CD22
Journal of Biological Chemistry·2023· 5 citedOpen Access
Abstract 3558: A novel and versatile cytokine empowered DNA vaccine platform with superior immune activating potential
Cancer Research·2022
“Built‐in” PD‐1 blocker to rescue NK‐92 activity from PD‐L1–mediated tumor escape mechanisms
The FASEB Journal·2021· 8 citedOpen Access
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
OncoImmunology·2021· 20 citedOpen Access
Combinatorial CAR design improves target restriction
Journal of Biological Chemistry·2020· 10 citedOpen Access
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Molecular Therapy·2020· 26 citedOpen Access
Combinatorial CAR design improves target restriction
2020· 2 citedOpen Access
Colorectal cysts as a validating tool for CAR therapy
BMC Biotechnology·2020· 3 citedOpen Access
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunology Immunotherapy·2019· 1 citedOpen Access
Abstract 1422: Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Cancer Research·2019
Abstract 1422: Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Clinical Research (Excluding Clinical Trials)·2019
Abstract 2318: Combinatorial IGK-CD19 CAR primarily targets IgK+ malignant B-cells and is less prone to serum IgG inhibition
Immunology·2019
Abstract 2318: Combinatorial IGK-CD19 CAR primarily targets IgK+ malignant B-cells and is less prone to serum IgG inhibition
Cancer Research·2019
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunology Immunotherapy·2019· 15 citedOpen Access
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Blood Advances·2019· 58 citedOpen Access
Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT–tamoxifen hybrid therapy
npj Breast Cancer·2019· 136 citedOpen Access
Biphasic mechanosensitivity of T cell receptor-mediated spreading of lymphocytes
Proceedings of the National Academy of Sciences·2019· 93 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Sébastien Wälchli(22), Else Marit Inderberg(20), Gunnar Kvalheim(16), Hakan Köksal(14), June H. Myklebust(12), Erlend B. Smeland(10), Laurent Limozin(8), Kheya Sengupta(8), Gustav Gaudernack(8), Sólrún Melkorka Maggadóttir(7), Sylvie Pollmann(7), Marit Renée Myhre(6), Nadia Mensali(6), Anne Fåne(6), Fuwei Pi(4), Theodossis A. Theodossiou(3), Astrid Wahl(3), Sarah E. Josefsson(3), Yngvild Nuvin Blaker(3), Klaus Beiske(3)